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Abstract
To determine the importance of dengue 2 virus (DEN2V) envelope (E) protein glycosylation, virus mutants in one or both of the N-linked
glycosylation motifs were prepared. We found that while the E2 mutant virus (N153Q) replicated in mammalian and mosquito cells, the E1
(N67Q) and E1/2 (N67Q and N153Q) mutant viruses were unable to grow in mammalian cells. Infection of C6/36 mosquito cells with either the
E1 or E1/2 mutants resulted in the introduction of a compensatory mutation, K64N, restoring glycosylation in the area. All mutants replicated
similarly in inoculated Aedes aegypti mosquitoes, with no change in their mutations. These results suggest that N-linked glycosylation of the E
protein is not necessary for DEN2V replication in mosquitoes, however N-linked glycosylation at amino acid N67 (or nearby N64) is critical for
the survival of the virus in either mammalian or insect cell culture.
Published by Elsevier Inc.Keywords: E glycosylation; Dengue virus; Flavivirus; MosquitoesIntroduction
The dengue viruses (DENVs) are the most significant vector-
borne human viral pathogens and cause 50 million or more
infections worldwide each year, resulting in approximately
24,000 deaths (WHO, 2007). DENVs are members of the family
Flaviviridae, genus Flavivirus, that contains several other im-
portant human pathogens (e.g., yellow fever, Japanese ence-
phalitis [JE], tick-borne encephalitis [TBE], West Nile [WN],
and St. Louis encephalitis [SLE] viruses). The single-stranded,
positive-sense RNA genome of flaviviruses encodes three struc-
tural proteins: capsid (C), premembrane (prM), and envelope (E)
proteins; and seven nonstructural proteins. The E glycoprotein is
the major component of the virion surface and is arranged as a
smooth and dense lattice of 90 head-to-tail E homodimers that
are complexed with the M protein (Kuhn et al., 2002).⁎ Corresponding author. Fax: +1 970 221 6476.
E-mail address: jtr1@cdc.gov (J.T. Roehrig).
0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2007.05.007The E protein induces protective immunity, and flavivirus
serological classification is based on its antigenic variation. The
crystal structure of the ectodomains of the TBEV (Rey et al.,
1995), DEN2V (Modis et al., 2003) and DEN3V (Modis et al.,
2005) E glycoprotein homodimers has been solved (Fig. 1).
Each E protein monomer is comprised of three structural and
functional domains: domain I (the hinge region, containing the
amino-terminus); domain II (responsible for stabilizing the
dimer and containing the fusion peptide, amino acids 98–110);
and domain III (Ig-like domain containing putative receptor
binding motifs) (Crill and Roehrig, 2001; Rey et al., 1995).
Individual amino acid residues critical for virus attachment and
conformational changes associated with membrane fusion are
beginning to be defined (Modis et al., 2003), as well as residues
involved in flavivirus serological cross-reactivity (Crill and
Chang, 2004).
The recent identification of the mannose-specific C-type
lectin, dendritic-cell-specific ICAM3-grabbing non-integrin
(DC-SIGN), as a host–cell receptor for DENVs (Navarro-
Fig. 1. Atomic structure of the DEN2V E protein homodimer showing location
of N-linked glycosylation motifs (N67, orange/cyan, and N153, orange/green)
and K64 (magenta) which is the site of the compensatory K64N mutation
(Modis et al., 2003). Views: lateral, panel A; top, panel B. Envelope protein
structural domain designations: I (red), II (yellow), III (blue).
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glycan–lectin interactions may be important for viral attach-
ment. However, the potential impact of differences in the
number and type of carbohydrate moieties on the virion surface
proteins, and their role in virus–host interactions necessary for
replication and transmission, remain poorly understood.
In most flaviviruses, the E protein contains one or more
potential N-linked glycosylation motifs of the form N-X-T/S
(where X=any amino acid). The number and location of
glycosylation motifs in the E protein varies considerably both
between and within flavivirus species (Adams et al., 1995;
Ishak et al., 2001; Johnson et al., 1994; Scherret et al., 2001;
Vorndam et al., 1993; Wengler et al., 1985; Winkler et al., 1987;
Wright, 1982). The most commonly observed glycosylation
motif in the flavivirus E protein occurs in domain I, at residues
N153 or N154 (Fig. 1). However, not all flaviviruses, such as
Kunjin virus, are glycosylated at this N residue. In structural
models of the E protein, the N153 residue is proximal to the
fusion peptide at the tip of domain II of the associated dimer
(Modis et al., 2003; Rey et al., 1995).
It is well established that addition of a glycan at N153 is
not an absolute requirement for infectivity. Several naturally
occurring flaviviruses lack this N-linked glycan (Roehrig et
al., 1998; Scherret et al., 2001; Vorndam et al., 1993). Passage
in cell culture or mice or exposure to altered environments has
also been associated with mutations of the N153 glycosylation
motif. Phenotypic changes in these nonglycosylated viruses
include reduced expression of E protein, altered membrane
fusion activity, plaque size variation in Vero cells, reduced
virus replication in mosquito cells, and loss of neuroinva-
siveness in animal models of infection (Beasley et al., 2005;
Guirakhoo et al., 1993; Kawano et al., 1993; Lee et al., 1997;
Mason et al., 1987; Scherret et al., 2001; Shirato et al., 2004;
Vorndam et al., 1993). Given the proximity of the N153
residue to the fusion-active peptide, it has been hypothesized
that carbohydrate additions to this region may contribute to Eprotein stability and thereby protect against premature
conformational changes during virus maturation and secretion
(Crill and Chang, 2004; Modis et al., 2003; Rey et al., 1995).
Removal of the carbohydrate at N153 has also been
associated with the reduction in levels of expressed WNV
virus-like particles (VLPs) in certain cell types (Hanna et al.,
2005).
In addition to the N153 glycan, the four DENV serotypes
share a flavivirus unique N-linked glycosylation motif at N67
(Deubel et al., 1986; Mason et al., 1987; Osatomi et al., 1988;
Zhao et al., 1986), located on the upper surface of domain II
(Crill and Chang, 2004; Mukhopadhyay et al., 2005). It should
be emphasized that the utilization of both glycosylation motifs
in DENVs has been determined for only a limited number of
strains within each serotype, and variability among naturally
circulating virus populations remains largely uncharacterized.
Recent evidence with DENV suggests that infection of dendritic
cells bearing DC-SIGN receptors is mediated through the
carbohydrate at N67 (Pokidysheva et al., 2006).
Using site-directed mutagenesis of an infectious cDNA
clone of DEN2V permitted us to investigate directly the
specific phenotypic changes attributable to the presence or
absence of glycans, without the need for glycosidase or
tunicamycin treatment, or the limitations of studies involving
naturally occurring variants or VLPs. In this report, we
describe the construction of DEN2V 30P-A mutants that lack
the N67, N153, or both glycosylation motifs in the E protein.
The effect of deglycosylation on the phenotypes of the mutant
viruses was examined in continuous cell lines and inoculated
Aedes aegypti mosquitoes, the primary arthropod vector for
DENV. These results suggest that while N-linked glycosylation
of the DEN2V E protein at amino acid N67 (or nearby N64) is
not necessary for DEN2V replication in mosquitoes, it is
critical for the survival of the virus in either mammalian or
insect cell culture.
Results
Derivation of mutant viruses
The fidelity of replication of the DEN2 30P-A infectious
clone pD2/IC-30P-A in Escherichia coli was tested by
sequencing the complete DEN2V genomic cDNA in the
plasmid pD2/IC-30P-A5, which was obtained by passaging
the original pD2/IC-30P-A plasmid through four cycles of
electroporation and growth in XL-1 Blue cells. No mutations
were found. Full genomic sequencing of the DEN2V cDNA in
the mutant infectious clones verified the presence of only the
engineered E1, E2, and E1/2 gene mutations. The engineered
mutations were confirmed in all viruses produced by transfec-
tion (Table 1).
The E2 mutant virus was successfully recovered by
transfection of LLC-MK2 cells with RNA transcribed from
the E2 clone. The E1 and E1/2 mutant viruses were recovered
only from transfected Aedes albopictus C6/36 cells and not
transfected primate LLC-MK2 or Vero cells. Virus-positive
transfections were identified by IFA reactivity with DEN2V-
Table 1
Glycosylation motif mutants of DEN2 16681
Mutant Amino acid a 16681 Sequence b Mutant sequence
E1 N67 N T T Q T T
AAC ACA ACA CAG ACA ACA
E2 N153 N D T Q D T
AAT GAC ACA CAG GAC ACA
E1/2 N67 N T T Q T T
AAC ACA ACA CAG ACA ACA
N153 N D T Q D T
AAT GAC ACA CAG GAC ACA
a E protein amino acid change.
b Amino acid sequence over nucleotide sequence; bold letters indicate altered
amino acid or nucleotide.
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MK2 cells for the E2 mutant (data not shown).
Confirmation of E protein glycosylation status
We attempted to confirm the glycosylation status of the
mutant E proteins in two ways. First, the complete E protein
gene was sequenced for all three mutant viruses. The
sequencing results confirmed that only the introduced mutations
were present in recovered mutant viruses. The sequencing
results also determined that for the E1 and E1/2 mutants, a
compensatory mutation at amino acid 64 (AAA→AAT;
K→N) occurred in C6/36 cells after two passages that re-
established the glycosylation motif in this area. We could not
reproducibly demonstrate differences in molecular mobilities of
the E protein mutants by SDS-PAGE followed by immunoblot
detection using 10% minigels, large-gel (20 ml) format, or 4–
12% mini-gradient gels.
Immunological characterization of the glycosylation mutant
E proteins
The E protein epitope expression in acetone-fixed, virus-
infected C6/36 cells was probed by MAb IFA assay. No
significant antigenic changes (N4-fold difference in reactivity)
were seen with any MAb tested (Table 2). These experiments
were performed with low passage virus to minimize accumula-
tion of the compensatory mutation at N64 in the E1 and E1/2
mutant viruses.Table 2
Epitope mapping of DENV glycosylation mutants using IFAwith low passage,
virus-infected C6/36 cells a
Epitope MAb 30P-A E1 E2 E1/2
A1 6B6C-1 200 390 190 190
A2 4E5 40 20 40 40
A4 2H3 250 250 250 500
C1 1B4C-2 310 310 310 630
B1 3H5 1250 1670 1670 2500
B2 9A3D-8 630 1250 1250 630
B4 1A1D-2 310 80 80 160
prM 2H2 80 80 40 80
– HIAF 80 30 160 160
a Antibody reactivities reported as ng/ml at end-point.Growth properties and plaque morphology in cell culture
Ten-day growth curves were performed in Vero and C6/36
cells with the 30P-A and E2 viruses and were assayed by
plaque assay in LLC-MK2 cells (Figs. 2A and B). Maximum
viral titers achieved by the E2 virus were about 10-fold
lower than 30P-A in both cell types. Other cell types tested
for viral growth were BHK-21, KB, L929, and the AP61
mosquito cells. Virus-infected cell supernatants were har-
vested at 7 days post-infection. While the 30P-A parental
virus grew in all cells types, the E2 virus failed to grow in
L929 cells (data not shown). There was little difference
between the growth of 30P-A virus and E2 in intrathor-
acically (I.T.) inoculated A. aegypti mosquitoes (Fig. 2C),
and all mosquitoes were infected. We used I.T. mosquito
inoculation because the 30P-A wild-type strain infects our
variety of A. aegypti mosquitoes very poorly following oral
feeding.Fig. 2. Growth curve of DEN2V 30P-A and the E2 glycosylation mutant.
Comparison of growth characteristics of DEN2V glycosylation mutants in
(A) Vero cells; (B) C6/36 cells; (C) mosquitoes. Viruses used: E2 (O), 30P-A (▴).
Table 3
Growth and stability of E1, E1/2, and 16681 viruses
D2/IC a Mutation Day
P.I.
Vero cells C6/36 cells Mosquitoes
% K64 b % K64b
E1 N67Q Start No growth 100 100
2 nt c nt
4 50 nt
6 50 nt
8 50 nt
10 50 nt
12 50 nt
14 nd 100
E1/2 N67Q N153Q Start No growth 100 100
2 nt nt
4 50 nt
6 50 nt
8 10 nt
10 10 nt
12 10 nt
14 nd d 100
30P-A – Start Growth and stable 100 100
2 nt nt
4 nt nt
6 nt nt
8 nt nt
10 nt nt
12 100 nt
14 nd 100
a Starting passage (p) level of viruses: E1, C6/36 p2; E1/2, C6/36 p1.
b Percent of virus with wild-type K at 64 (vs. compensatory mutation to N)
based on comparison of sequence signal strength.
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the E1 and E1/2 mutants did not grow in mammalian cell
culture (Vero, LLC-MK2, L929, BHK-21, or KB cells) as
measured by assay for infectious virus from infected cell
culture supernatants or antigen detection by IFA on virus-
infected cells (data not shown). Twelve-day growth curves of
E1, E1/2, and 30P-A viruses were performed in C6/36 cells
(Fig. 3A). Growth curves of these three viruses as measured by
qRT-PCR or TCID50 were similar in C6/36 cells. Mean viral
titers for each virus were: 9.2 log10 TCID50/ml (30P-A virus),
8.5 log10 TCID50/ml (E1 virus), and 8.6 log10 TCID50/ml (E1/2
virus) at 12 days p.i. To follow the accrual of the K64N
compensatory mutation in the E1 and E1/2 mutant viruses, we
sequenced these viruses over the course of the C6/36 growth
curve, and the peak heights of the mixed sequence signal at
amino acid 64 were compared. The sequencing results revealed
a rapid accumulation of the K64N compensatory mutation
(Table 3). The compensatory mutation was observed by day 4
p.i., with the resultant virus containing a 50:50 ratio of K64N
virus:N67Q virus throughout the growth curve. The E1/2
mutant virus demonstrated a 90:10 ratio of K64N:N67Q virus
by 8 days p.i. Further inspection of the amino acid sequences
surrounding the E67 and E153 glycosylation motif suggests
that while mutations in the N153 region should result in a
stably deglycosylated motif, the N67 region could support at
least 4 compensatory mutations the would result in the re-
acquisition of carbohydrate in this area (e.g., K64N, T66N,Fig. 3. Viral growth in C6/36 cells and Aedes aegypti mosquitoes as measured
by qRT-PCR. Panel A, growth in C6/36 cells. Panel B, growth in A. aegypti
mosquitoes. Key: (●) E1 mutant, (■) E1/2 mutant, and (▴) 30P-A virus.
c Not tested.
d Not done.T68N, T70N) (Fig. 4). This redundancy likely reflects the
critical need for glycosylation to occur in this region.
Infection of vector mosquitoes with E1 and E1/2 viruses by
intrathoracic inoculation
Because glycosylation at N67 seemed to be critical for the
growth of the E1 and E1/2 mutants viruses in vitro, we
hypothesized that removal of the N67 glycan may be associated
with restricted host range in vivo. To investigate the growth
characteristics of these viruses in the whole organism, viral
infectivity was assayed in A. aegypti mosquitoes infected by
I.T. inoculation with E1, E1/2 or 30P-A viruses (Fig. 3B).
Infection rates for the 30P-A wild-type virus and the mutant
viruses were essentially identical: 30P-A virus, 17/17 positive
mosquitoes (100%); E1 virus, 54/59 positive mosquitoes
(91%); E2 virus, and E1/2 virus, 54/59 positive mosquitoes
(91%) by day 14 p.i. Growth curves of the E1/2 and 30P-A
viruses in mosquitoes assayed using qRT-PCR were similar, andFig. 4. Amino acid sequence around the E protein N-linked glycosylation sites.
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(Fig. 3B). Mean peak viral titers for each of these viruses were:
6.2 log10 TCID50/ml (30P-A virus), 5.2 log10 TCID50/ml (E1
virus), and 5.0 log10 TCID50/ml (E1/2 virus) at 14 days p.i.
Sequencing of the day 14 p.i. viruses showed that in contrast to
virus-infected C6/36 cells, all three mutant viruses were
genetically stable in infected mosquitoes. It is of interest that
while the measurements of genomic equivalents and infectious
virus are similar using the qRT-PCR or TCID50 methods with
virus-infected C6/36 cells, the measurement of genomic
equivalents is about 100-fold higher than the viral titers for
the infected mosquito specimens.
Discussion
Oligosaccharides on glycoproteins are known to play an
important role in the initiation of folding and the formation of
biologically active tertiary structures and may help to protect
against proteolytic digestion, thus influencing virus immuno-
genicity. Evidence concerning the dependence of the flavivirus
E protein on glycosylation for proper conformation and
functional activity is varied. JEV, which has a single
glycosylation site (at N153), showed a reduced ability to
produce extracellular E and NS1 proteins in the presence of
tunicamycin, implicating the necessity of glycosylation for
protein expression (Mason, 1989). However, in three separate
studies, deglycosylation of the TBE virus E protein was shown
to have no effect on antigenic expression, although a loss of
resistance to denaturation with sodium dodecyl sulfate, reduced
plaque size and titer in simian and mosquito cells, and marked
reduction in mouse neurovirulence was observed (Guirakhoo et
al., 1989; Pletnev et al., 1993; Winkler et al., 1987). The
deglycosylation of DENV in this study also had no effect on
antigenic expression of the E protein. For SLEV, no clear
correlation between virulence characteristics and glycosylation
pattern was observed in a study of seven isolates (Vorndam et
al., 1993). It has been suggested that virus strains may exist as
mixed populations of virions with both glycosylated and non-
glycosylated E proteins. Most recently, a study of plaque
purified variants of WNV found that glycosylation of the N153
residue was a molecular determinant of neuroinvasiveness
(Beasley et al., 2005; Shirato et al., 2004).
The phenotypic changes observed for all three mutant
viruses (E1, E2, and E1/2) when compared to DEN2V 30P-A
virus in mammalian cell culture suggest that glycans at both
N153 and N67 promote viral infectivity and contribute to E
protein function. Removal of the N67 glycan, however, had a
more severe effect on viral fitness than removal of the N153
glycan. It is also interesting to note that infectious virus lacking
the N67 site could not be produced following transfection of
LLC-MK2 and Vero cells, and N67 mutant viruses derived in
C6/36 cells grew poorly or not at all in a variety of mammalian
cells. Since we could find no evidence of intracellular viral
antigen in E1 or E1/2 virus-infected mammalian cells, we
conclude that viral replication leading to extracellular particle
formation does not occur in mammalian cells. The conclusion
that removal of the N67 glycosylation site is severely cripplingto virus replication is supported by the observation that unlike
N153, no spontaneous DENV mutants have been reported that
contain mutations ablating N67 glycosylation, and our N67
mutants rapidly accrued a compensatory mutation (K64N) that
resulted in the restoration of the glycan in this area.
We could not reproducibly show differences in the
molecular mobilities of these variably glycosylated E proteins
by SDS-PAGE. The reason for this is unclear, however we
believe the poor resolution is due to two reasons. First, since
the deglycosylation at N67 is rapidly replaced by glycosylation
at K64N in C6/36 cells, we are likely getting mixed viral
populations with the E1 and E1/2 viruses. We tried to
minimize this effect by using virus pelleted directly from cell
culture fluid thorough a 20% sucrose cushion, and not gradient
purified virus that requires longer growth periods. Because of
the low concentration of virus prepared in this way, the
concentration of E protein loaded on the gel could not be
directly determined and required detection by immunoblotting.
Additionally, the E protein did not stain well directly because
of serum protein contaminants not removed by the pelleting
process. The immunoblotting resulted in bands more diffuse
than expected with the low E protein concentrations used thus
making precise identification of molecular mobility shifts
difficult. Second, unlike flaviviruses derived from mammalian
cells where the carbohydrate moieties are processed to
complex or high mannose varieties, C6/36 cell-derived E
proteins contain only the tri-mannose core. This fact means
that the expected mobility shift of C6/36 cell-derived mutant E
proteins is quite small, much smaller than that expected with
mammalian cell-derived virus. Our sequencing of the initial
viral inoculums and the resultant viruses at the end of each
experiment does, however, confirm the glycosylation status of
each virus.
The oligosaccharide attached at the N153 site is proximal to
the fusion peptide at the distal end of the domain II of the
associated E monomer and close to the region where prM and E
are believed to interact (Fig. 1) (Modis et al., 2003; Zhang et al.,
2003). It has been postulated that the N153 glycan could play a
role in stabilizing the interaction between subunits of the mature
E protein dimer by partially occluding the fusion peptide (Rey et
al., 1995). The entry of flaviviruses into cells is mediated by a
pH-dependent conformational change in the E protein that
initiates an irreversible conformational change from dimer to
trimer. Trimerization is critical for virus fusion with endosomal
membranes following uptake by receptor-mediated endocytosis
(Allison et al., 1995; Stiasny et al., 1996). Mutant DENVs
lacking the E protein N153 glycosylation site have previously
been shown to have altered pH-dependent fusion activity
(Guirakhoo et al., 1993; Lee et al., 1997).
Although the pathogenesis of dengue infection is still poorly
understood, studies suggest that immature dendritic cells are
target cells of infection in humans following the bite of an
infected mosquito (Wu et al., 2000). DC-SIGN has been
implicated as a DENV cell receptor on dendritic cells (Navarro-
Sanchez et al., 2003; Tassaneetrithep et al., 2003). Studies using
concavalin A confirmed that α-mannose carbohydrate residues
participate in virus attachment to DC-SIGN. Interestingly, a
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positions N67 and N153, uses DC-SIGN more efficiently than a
DEN2V strain which uses only the N-glycosylation site at
position N67 (Navarro-Sanchez et al., 2003). That being said,
structural studies of DENV interacting with the carbohydrate
recognition domain (CRD) of DC-SIGN by cryo-electron
microscopy demonstrated that one CRD bound to two
glycosylation sites at N67 of two neighboring E proteins. The
N153 glycosylation site did not appear to interact with the CRD
of DC-SIGN. In a collaborative study, we are currently using
these mutant viruses to evaluate further the contribution of DC-
SIGN to DENV infection in human dendritic and other DC-
SIGN-bearing cells.
We do not yet know why glycosylation of the E protein DII
at either N67 in mammalian cells or K64N upon passage in
mosquito cells is critical for virus growth. The loss of
carbohydrate might alter virus-receptor binding, however
none of the mammalian cells tested have been shown to have
DC-SIGN on their surface, and virus binding to high affinity
cell receptors has been most closely associated with DIII of the
E protein. The MAb mapping of the mutant viruses suggests
native E protein folding. One possibility is that the loss of the
DII carbohydrate affects other steps in virus replication besides
cell attachment, e.g., virus-mediated cell membrane fusion or
viral maturation. We have shown previously that loss of the
DENV N153 glycosylation motif resulted in an increase in the
pH required to trigger fusion.
The entry mechanism of flaviviruses into cells is still poorly
understood. It has been suggested that WNVenters mammalian
P388D1 cells through receptor-mediated endocytosis (Gollins
and Porterfield, 1985). Studies with JEV and DEN2V suggest
that these viruses enter C6/36 cells by direct penetration of the
plasma membrane (Hase et al., 1989). This last study also
suggested that DENV enters peripheral blood monocytes
through direct plasma membrane penetration. Further studies
on flavivirus entry, perhaps with these mutant viruses, are
needed to understand better the effects E protein deglycosyla-
tion has on this aspect of virus replication. Little is known about
viral replication in mosquitoes at the cellular level. We are
currently examining these viruses for their ability to mediate
membrane fusion.
In summary, the present study demonstrates that glycosyla-
tion at both N153 and N67 of the E protein contributes to the
host range and infectivity of DEN2V. However, additional
research and much improved understanding of the role of
glycans in virus–host interactions will be required to ascertain
the specific way in which E protein glycosylation may mediate
pathogen recognition patterns, host range, virulence, and
transmissibility.
Materials and methods
Plasmids and viruses
The DEN2V 16681 was isolated in 1964 from a dengue
shock syndrome (DSS) patient in Thailand (Kinney et al.,
1997). Derivation of the DEN2V full-length infectious cDNAclone, pD2/IC-30P-A, and the 30P-A virus intermediate clones
F1 and F2 has been described previously (Kinney et al., 1997).
Introduction of mutations into DEN2V 30P-A F1 and
F2 plasmids
F1 and F2 plasmids were used as templates for site-directed
mutagenesis to construct the mutant full-length cDNA clones
E1, E2, and E1/2. Amino acid substitutions were chosen to
introduce the least amount of conformational change in the E
protein molecule (Table 1). Oligonucleotide primers were
designed for PCR mutagenesis to make the following amino
acid changes to the glycosylation sites of the 30P-A virus E
glycoprotein: N67→Q67 (E1), N153→Q153 (E2), both
N67→Q67 and N153→Q153 (E1/2). Mutation E1 was intro-
duced at genome nucleotide positions 1135–1137 in the F1
plasmid by using the QuikChange Site-Directed Mutagenesis
Kit (Stratagene). Mutation E2 was made in plasmid F2 by
using a forward primer containing the SphI site and the desired
mutation at genome nucleotide positions 1393–1395, and a
reverse primer containing the BstXI site at genome nucleotide
position 2247. DNA containing the E2 mutations was
amplified by PCR, restricted with SphI and BstXI, purified
by agarose gel electrophoresis, and ligated into SphI/BstXI-
restricted F2 plasmid.
Mutant F1 and F2 plasmid DNAwas extracted from bacterial
cell culture using the QIAprep Spin Miniprep Kit (Qiagen).
Clones were screened by sequencing across the mutation sites in
order to select those containing the desired mutation. Plasmid
DNA from selected clones was then extracted from large-scale
bacterial culture using the QIAGEN Plasmid Midi or Maxi Kit
(Qiagen) and fully sequenced to ascertain that no spurious
mutations had been introduced.
Sequence analysis of cDNA was conducted using the ABI
PRISM™ Dye Terminator Cycle Sequencing Ready Reaction
Kit with Amplitaq® DNA Polymerase FS (PE Applied
Biosystems) as recommended by the manufacturer and
analyzed by using a Model 373A or 377 Prism automated
DNA sequencer (PE Applied Biosystems). Both strands of the
target cDNA were sequenced.
Construction of mutant full-length infectious cDNA clones
The SphI-KpnI fragment (3113 bp) of the DEN2 30P-A
clone was replaced with a mutant F2 sequence to generate the
E2 full-length infectious clone. The SstI-SphI fragment
(1414 bp) of the 30P-A clone was replaced with the mutant
F1 sequence to generate the E1 full-length infectious clone. The
E1/2 full-length (double mutant) infectious clone was generated
by inserting the mutant F1 SstI-SphI fragment into the E2 full-
length clone.
Following ligation mutated plasmids were transformed by
electroporation and transformed bacteria were plated onto YT
agar with 70 μg/ml of ampicillin and incubated for approxi-
mately 24 h at 37 °C. Plasmid DNA from selected colonies that
had been grown overnight in 2X YT broth was extracted from
bacterial cell culture and was sequenced across the mutation
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Large-scale plasmid preparations of mutant full-length clones
were grown, and the full-length genomic cDNA of each mutant
clone was sequenced to assure that there were no additional
mutations in the cDNA beyond those introduced at the potential
E protein glycosylation motifs.
Production of viruses
Mutant plasmids were linearized at the unique XbaI site
engineered at the 3′-end of the DEN2V genomic cDNA, and
virus-specific RNA was transcribed. For isolation of the E2
mutant virus, LLC-MK2 cells were transfected by electropora-
tion as previously reported (Kinney et al., 1997). For isolation
of the E1 and E1/2 mutant viruses C6/36 cells were used for
transfection. Transfected cells were incubated at 37°C for
5–13 days. When cytopathic effects (CPE) were evident, virus-
containing cell culture was titrated in Vero cells by double
overlay plaque assay as previously described (Miller et al.,
1989) or by a 50% tissue culture infectious dose (TCID50) assay
in C6/36 cells (see below).
To confirm the presence of DENV antigen in transfected
cells, acetone-fixed cells were analyzed by indirect immuno-
fluorescence assay (IFA) using a DEN2V-specific monoclonal
antibody (MAb) 3H5 (Henchal et al., 1985) and polyclonal
anti-DEN2 New Guinea C hyperimmune mouse ascitic fluid
(HMAF). Fluorescein isothiocyanate (FITC)-conjugated goat
anti-mouse IgG (Jackson Immunoresearch Laboratories, Inc.,
West Grove, PA) was used as the secondary antibody (Gubler,
1987).
Reverse transcription-PCR (RT-PCR) genomic sequencing
was used to verify the presence of introduced mutations in virus
seeds and in all working virus stocks. Viral RNAwas extracted
by using the QIAamp Viral RNA Kit (Qiagen) and then
amplified by RT-PCR as described previously (Lanciotti et al.,
1992). RT-PCR products were purified using the QIAquick
PCR Purification Kit (Qiagen) prior to sequencing as described
above.
Replication in cell culture
Ten- or twelve-day virus growth curves were performed by
infecting primate Vero or mosquito C6/36 cells at a multiplicity
of infection (m.o.i.) of 0.01 PFU per cell. Viral growth was also
evaluated in BHK-21, mosquito AP61, human KB, and murine
L929 cells. Cell culture supernatants were titered by plaque
assay in LLC-MK2 cells by using the double overlay plaque
assay method. Neutral red overlay was added to cell cultures 7
days post-infection.
Analysis of viral proteins
C6/36 cells were infected with virus at an m.o.i. of 5.0–10.0
for virus purification. All virus seeds were C6/36 passage 4.
Cell culture supernatant was harvested 6–10 days after
infection, when there was significant evidence of CPE in the
cell monolayer. Virus was partially purified by pelleting througha 20% sucrose cushion. Molecular mobility of the viral E
proteins was evaluated by SDS-polyacrylamide gel electro-
phoresis (PAGE) and immunoblot (Laemmli, 1970; Towbin et
al., 1979). Purified protein was reduced and subjected to SDS-
PAGE on 10% Tris–glycine Pre-Cast Gel minigels as recom-
mended by the manufacturer (Novex Novel Experimental
Technology, San Diego, CA). Protein migration was also
analyzed by SDS-PAGE on 20 ml 10% and 4–12% gradient
minigels. After electrophoresis, gels were either stained with the
Silver Stain Plus Kit (Bio Rad), fixed and dried using the
DryEase™ Mini-Gel Drying System (Novex), or they were
blotted onto polyvinylidene difluoride (PVDF) membranes
using the XCell II™ Blot Module Western transfer apparatus
(Novex) for analysis by Western blotting. The immunoblot
procedure has been previously described (Roehrig et al., 1998).
Quantitative RT-PCR (qRT-PCR)
The method for measuring levels of viral RNA (vRNA)
using qRT-PCR has been previously published (Butrapet et al.,
2006).
TCID50 assay
C6/36 cells were seeded into the inner 60 wells of 96-well
flat-bottomed microtiter plates at a density of 1.2×105 cells/
well. Twenty-four hours later, wells were infected with a 10-fold
dilution series of virus and cultured at 28 °C. Twelve days later,
cell culture medium was removed, and cells were fixed with
85% ice-cold acetone for 20 min at −20 °C or overnight at 4 °C.
After the removal of the acetone, the plates were blocked with
200 μl of blocking buffer (3% goat serum in 0.1% Tween 20)
for 1 h at room temperature. Viral antigen was detected by
enzyme-linked immunosorbent assay using a murine DEN2V-
reactive antibody, goat anti-mouse alkaline phosphatase-
conjugated antibody, and Sigma 104 substrate (Roehrig et al.,
1998). The reactions were stopped with 3 N NaOH. Absorbance
(A405 nm) values greater than 2-fold over background
absorbance were considered positive. TCID50 titers were
calculated using the method of Reed and Muench. Authentic
DEN2V strain 16681 was included as a positive virus control.
Epitope mapping
Due to the inability of the E1 and E1/2 viruses to grow to
high titer without the accrual of compensatory mutations, E
protein epitope mapping of mutant viruses was performed by
indirect fluorescent antibody (IFA) assay of acetone-fixed, C6/
36 cells infected with low passaged sequence confirmed viruses
(Gubler, 1987). A panel of well-defined, DENV-reactive
monoclonal antibodies were used for epitope mapping (Roehrig
et al., 1998).
Mosquito infection
Replication of mutant viruses was studied in the F1
generation of wild-caught A. aegypti mosquitoes from Salina,
422 J.E. Bryant et al. / Virology 366 (2007) 415–423Puerto Rico. Mosquitoes were inoculated with E1, E2, or E1/
2, or clone-derived 30P-A by intrathoracic inoculation. Adult
female mosquitoes, aged 7–8 days, were cold anesthetized
and inoculated using a microcapillary needle that had been
pulled to a point with a Narishige (Tokyo) needle puller. E1,
and E2 virus stocks were standardized to 6.0 log10 pfu/ml,
and 0.34 μl was injected into each mosquito (approximately
315 pfu/mosquito). For E1/2 virus-inoculated mosquitoes,
virus was standardized to 4.0 log10 (3.4 pfu/mosquito), as this
was the maximum titer achievable in cell culture. Two groups
of control mosquitoes were infected with the parental strain
(30P-A) at 315 and 3.4 pfu/mosquito, respectively. Inoculated
mosquitoes were maintained in cartons at 27 °C and 85%
humidity and fed 5% sucrose solution. Three mosquitoes
were collected at 48-h intervals for the 14-day incubation
period, at the end of which all remaining mosquitoes were
frozen and stored at −70 °C for processing (Miller et al.,
1989).
Individual mosquitoes were triturated in BA-1 medium
(M199 medium with Hank's salts, 1% bovine serum albumin,
100 U/ml of penicillin, 100 μg/ml of streptomycin, and 1 μl/ml
of fungizone) by using a Mixer Mill apparatus (Qiagen,
Valencia, CA) and suspensions were clarified by centrifugation.
Clarified supernatant was titrated for virus by either TCID50
assay in C6/36 cells or qRT-PCR for vRNA.
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